Close Menu

GeneProt and Large Scale Biology both announced cutbacks last week, as big pharma’s apparent reluctance to invest heavily in the companies’ technology began taking its toll. GeneProt, which had initially planned to establish a second industrial-scale proteomics facility in North Brunswick, NJ, by this fall, has now indefinitely postponed its expansion plans. LSBC, in an effort to reduce its cash burn rate, has laid off 31 percent of its workforce and reduced overall company spending by 30 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.